The majority of cuts will take place in December, according to a notice filed with the state of New Jersey this month.

With expansion into targeted markets and strategic diversification, UNH still has significant growth potential left.

PBMs, like Optum Rx, are the key counterweight to pharmaceutical companies’ otherwise unchecked monopoly power to set and raise drug prices.

UnitedHealth's aggressive M&A strategy and focus on data analytics drive growth and margin improvements, justifying a 'Strong ...

UnitedHealth Group(NYSE:UNH) is currently experiencing significant developments that are shaping its business trajectory.

The US Federal Trade Commission sued units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. on Friday, accusing ...

The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes ...

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

The Federal Trade Commission filed an action against the three largest prescription drug benefit managers or PBMs— CVS Health's ...

UnitedHealth Group's Optum Rx will join its peers in the big three pharmacy benefit managers by pulling Humira from some of ...

Notably, UNH is one of a handful of stocks that have increased their value in each of the last three years, but that still wasn’t enough for it to consistently beat ...

We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are ...